VolitionRx reports strong revenue growth from Nu.Q diagnostics, but wider-than-expected loss pressures investor sentiment.
Stock Earnings Results
May 15, 2026
Table of Contents
May 15, 2026
VolitionRx Limited (NYSE: VNRX) reported first-quarter 2026 results with strong year-over-year revenue growth, but shares came under pressure after the company posted a wider-than-expected loss.
VolitionRx is a diagnostics company developing blood-based tests using its Nu.Q technology platform, with applications across cancer detection, disease monitoring, and veterinary diagnostics.
The company reported a loss of $0.82 per share, wider than estimates for a loss of $0.70, representing a negative 17.1% earnings surprise. Revenue came in at $985,000, with revenue growth of 142.0%.
VolitionRx reported nearly $1.0 million in revenue for the quarter, supported by deferred revenue recognition tied to its Nu.Q Vet agreement with Heska.
The revenue increase showed progress in monetizing the company’s diagnostics platform, although the total revenue base remains small.
The bigger issue was profitability.
VolitionRx’s loss came in wider than expected, showing that the company is still facing cost pressure as it funds research, development, commercialization, and corporate operations.
Operating expenses rose to $6.3 million, up 8.6% year-over-year.
The increase was partly tied to severance costs and higher R&D expenses, which likely contributed to the wider loss.
The company ended the quarter with $3.1 million in cash and cash equivalents, up from $1.1 million at the end of December 2025.
VolitionRx also raised $7.3 million in capital during the quarter, helping support near-term operations.
Investors are likely to watch whether VolitionRx can turn diagnostics partnerships and revenue recognition into more consistent commercial traction.
The key areas are:
VolitionRx showed revenue growth, but the stock reaction suggests investors focused more on the earnings miss and ongoing cash needs.
For early-stage diagnostics companies, small revenue gains are not enough unless they point to a scalable commercial path. VolitionRx’s next test is whether it can grow revenue faster than expenses while reducing reliance on capital raises.
Platforms like LevelFields track earnings misses, backlog growth, government contracts, space-sector catalysts, and small-cap healthcare stock reactions together, helping investors identify when revenue growth is being offset by profitability and financing concerns.
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better investor.
AI scans for events proven to impact stock prices, so you don't have to.
LEARN MORE